DOCSLIB.ORG

Dose-Effect of Fenfluramine Use on the Severity of Valvular Heart Disease

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Dose-Effect of Fenfluramine Use on the Severity of Valvular Heart Disease International Journal of Obesity (1999) 23, 926±928 ß 1999 Stockton Press All rights reserved 0307±0565/99 $15.00 http://www.stockton-press.co.uk/ijo Dose-effect of fen¯uramine use on the severity of valvular heart disease among fen-phen patients with valvulopathy RLi1*, MK Serdula2, DF Williamson3, BA Bowman2, DJ Graham4 and L Green5 1Epidemic Intelligence Service, Epidemiology Program Of®ce and Division of Nutrition and Physical Activity; 2Division of Nutrition and Physical Activity; 3Division of Diabetes Translation, National Center for Chronic Disease Prevention and Health Promotion, Centers for Disease Control and Prevention, USA; 4Epidemiology Branch, USA; and 5Reports Evaluation Branch, Division of Pharmacovigilance and Epidemiology, US Food and Drug Administration, USA OBJECTIVE: To determine whether the severity of valvulopathy was associated with the dosage of fen¯uramine taken by fen¯uramine-phentermine users with valvulopathy. DESIGN: Out of 105 suspected valvulopathy case reports received by the US Food and Drug Administration (FDA) among fen¯uramine-phentermine users, 74 patients meeting FDA case de®nition for valvulopathy were included in this study. Patients with severe valvulopathy were classi®ed as those either undergoing valve replacement surgery or having severe aortic or mitral regurgitation; all other patients were considered to have less severe valvulopathy. RESULTS: The proportion with severe valvulopathy increased from 20 ± 66% with increasing fen¯uramine dosage from 40 mg=dto60 mg=d. Compared with patients taking<40 mg=d fen¯uramine, patients taking 60 mg=d had an adjusted odds ratio of 9.2 (95% con®dence interval 2.1 ± 40.8) for severe valvulopathy. CONCLUSION: Compared to patients with less severe valvulopathy, those with severe valvulopathy were substan- tially more likely to have taken 60 mg=d fen¯uramine. Keywords: dose ± effect; fen¯uramine-phentermine; severity of valvulopathy Introduction provides information about the dose-effect. The pur- pose of this study was to determine whether the severity of valvular heart disease among fen-phen Fen¯uramine is a serotonin-based appetite-suppres- users was associated with the dosage of fen¯uramine. sant drug which is widely used in combination with phentermine, commonly called fen-phen. On 8 July 1997, the Mayo Clinic reported 24 cases of valvular heart disease in women treated with fen-phen,1 who Subjects and methods had no history of valvulopathy. Subsequently, the US Food and Drug Administration (FDA) issued a Public Because the striking feature of the case reports Health Advisory requesting that physicians report received by FDA was the consistent involvement of additional cases of valvulopathy through MED- left-sided cardiac valve lesions, FDA established its WATCH, a medical product reporting system estab- case de®nition as the existence of either mild or 2 lished by FDA. Based on results from the prevalence greater aortic regurgitation (AR), or moderate surveys, which consistently found a higher than or greater mitral regurgitation (MR), or both as expected prevalence of valvulopathy among persons determined by echocardiography. At the time when 3 exposed to fen¯uramine or dexfen¯uramine, FDA fen¯uramine and dexfen¯uramine were voluntarily announced the voluntary withdrawal of fen¯uramine withdrawn from the market, FDA had received 105 and dexfen¯uramine from the market on 15 Septem- fen-phen case reports. Among them, 88 (84%) met ber 1998. FDA de®nition of valvulopathy. After excluding 14 Although the most recent studies provide further patients without complete information on drug expo- support to the association of appetite-suppressant sure and covariates, the ®nal study sample consisted 4±6 medications with valvulopathy, none of them of 74 fen-phen patients with valvulopathy. Patients with severe valvulopathy were classi®ed as those either undergoing valve replacement surgery or *Correspondence: Ruowei Li, Division of Nutrition and Physical Activity (Mailstop K26), Centers for Disease Control and having severe AR or severe MR; all other patients Prevention, 4770 Buford Hwy, N.E., Atlanta, were considered to have less-severe valvulopathy. GA 30341-3717, USA. w2 test was used to examine the difference in the E-mail: [email protected] Received 23 November 1998; revised 5 February 1999; accepted proportion of severe valvulopathy. Logistic regression 31 March 1999 analysis was used to determine whether the severity of Severity of valvulopathy and fen¯oramine use R Li et al 927 valvulopathy was related to the drug use, after adjust- Table 2 Odds ratios (OR) for severe valvulopathy ing for age, body weight at report, and the duration of Crude OR Adjusted OR a drug use. No interaction terms between duration and (95% CI) (95% CI) drug use were included in the model, because of their Age (10 y) 1.2 (0.7 ± 1.9) 1.3 (0.7 ± 2.4) statistical insigni®cance (P > 0.01). All statistical ana- Weight at Report (10 kg) 1.2 (1.0 ± 1.4) 1.1 (0.8 ± 1.4) lyses were done using SAS version 6.12.7 Duration (1 month) 1.0 (1.0 ± 1.1) 1.0 (1.0 ± 1.1) Fen¯uramine (mg=d) <40 1.0 (ref) 1.0 (ref) 40 1.4 (0.2 ± 8.4) 1.5 (0.2 ± 10.2) Results 60 9.0 (2.2 ± 36.4) 9.2 (2.1 ± 40.8) 95% CI 95% con®dence interval. aAdjusted for all other variables. Thirty-®ve out of 74 fen-phen patients (47%) were classi®ed as having severe valvulopathy, whereas 39 (53%) were classi®ed as having less severe valvulo- Discussion pathy. Among patients with severe valvulopathy, 17 underwent value replacement surgery, ®ve had severe AR, and 13 had severe MR. In all patients, the median This is the ®rst study to suggest that the severity of dosage for fen¯uramine and phentermine was cardiac valvulopathy was associated with fen¯ura- 60 mg=d (range 10 ± 220 mg=d) and 30 mg=d mine dosage, but not with phentermine dosage. (range 15 ± 60 mg=d) respectively, whereas the Among patients with valvulopathy, those with median duration of fen-phen use was 11 months severe valvulopathy were substantially more likely (range 1 ± 39 months). Table 1 shows that patients to have taken a higher dose of fen¯uramine with severe valvulopathy tended to use higher fen- (60 mg=d) than those with less severe valvulopathy. ¯uramine doses than those with less-severe valvulo- The mechanism of the drug-associated valvulo- pathy (82% of severe vs 38% of less-severe patients pathy is unclear. It has been speculated that serotonin took 60 mg=d, w2 15.08, P 0.0001). The propor- might be the link, because the injured valves look tion with severe valvulopathy increased from 20% identical to those observed in carcinoid-induced valv- (6=30) to 66% (29=44), as fen¯uramine dosage ular disease.1 An additional hypothesis is that phen- increased from 40 mg=d to 60 mg=d. Compared termine may impair the clearance of serotonin by the with patients taking <40 mg=d fen¯uramine, patients lung, which would allow abnormally high concentra- taking 60 mg=d had an adjusted or of 9.2 (95% tions of serotonin to reach the left side of the heart, con®dence interval 2.1 ± 40.8) for severe valvulopa- when it is taken together with fen¯uramine.9,10 thy (Table 2). The Hosmer and Lemeshow goodness- Because all the subjects in this study were treated of-®t tests indicated that the logistic model ®ts the with both fen¯uramine and phentermine, we cannot data well with goodness-of-®t statistic 1.3 reject the possibility that the dose-effect of fen¯ur- (P 0.9961).8 In contrast, both phentermine dosage amine on the severity of valvulopathy may have a and duration of drug use did not appear to be related phentermine-related threshold. to the severity of valvulopathy. Because data on initial body weight were not provided, weight at the time of report was used as a proxy. Patients with severe valvulopathy had a sig- Table 1 Description of cases of severe and less-severe ni®cantly higher weight at the time of report than valvulopathy those with less-severe valvulopathy, which may Severe Less-severe re¯ect differences in initial weight. Nevertheless, the valvulopathy vavulopathy effect of fen¯uramine dosage on severity of valvulo- (n 35) (n 39) pathy cannot be ascribed to differential body weight, Female 35.(100%) 38.(98%) because weight was not signi®cantly related to sever- Age (y) 44.3 (s.d. 9.6) 43.1 (s.d. 8.5) Weight at report (kg) 95.0 (s.d. 28.3) 87.1 (s.d. 18.6)* ity of valvulopathy in the logistic models. Fen¯uramine (mg=d) Although a previous study showed an association of <40 3.(9%) 14.(36%) valvulopathy with the duration of drug use,5 duration 40 3.(9%) 10.(26%) 60 24.(68%) 13.(33%) of drug use did not appear to be related to the severity > 60 5.(14%) 2.(5%) of valvulopathy in this MEDWATCH data. There are Phentermine (mg=d) several explanations. First, the duration of exposure <30 11.(32%) 13.(33%) 30 18.(51%) 21.(54%) depended upon the reporting physician's recall and > 30 6.(17%) 5.(13%) may have been underestimated for those patients who Duration of drug use (months) had previously used appetite-suppressants under the 6 9.(26%) 12.(31%) > 6 ± 12 15.(43%) 14.(36%) care of other physicians. Second, cardiac disorders > 12 ± 24 6.(17%) 10.(26%) may occur as early as a few weeks after drug expo- > 24 ± 5.(14%) 3.(8%) sure,6 whereas 93% of all patients in this study had Percentage may not add up to 100 because of rounding-off.
Load more

Recommended publications
  • Investigating Interactions Between Phentermine, Dexfenfluramine, and 5-HT2C Agonists, on Food Intake in the Rat
    Psychopharmacology DOI 10.1007/s00213-014-3829-2 ORIGINAL INVESTIGATION Investigating interactions between phentermine, dexfenfluramine, and 5-HT2C agonists, on food intake in the rat Andrew J. Grottick & Kevin Whelan & Erin K. Sanabria & Dominic P. Behan & Michael Morgan & Carleton Sage Received: 2 October 2014 /Accepted: 20 November 2014 # The Author(s) 2014. This article is published with open access at Springerlink.com Abstract Conclusions Dex-phen synergy in the rat is caused by a Rationale Synergistic or supra-additive interactions between pharmacokinetic interaction, resulting in increased central the anorectics (dex)fenfluramine and phentermine have been concentrations of phentermine. reported previously in the rat and in the clinic. Studies with 5- HT2C antagonists and 5-HT2C knockouts have demonstrated Keywords Synergy . BELVIQ® . Lorcaserin . Isobologram . dexfenfluramine hypophagia in the rodent to be mediated by Fen-phen actions at the 5-HT2C receptor. Given the recent FDA approv- al of the selective 5-HT2C agonist lorcaserin (BELVIQ®) for weight management, we investigated the interaction between Introduction phentermine and 5-HT2C agonists on food intake. Objectives This study aims to confirm dexfenfluramine- Fenfluramine (Pondimin) and dexfenfluramine (Redux) are phentermine (dex-phen) synergy in a rat food intake assay, anorectic agents which act to enhance serotonergic transmission to extend these findings to other 5-HT2C agonists, and to both through inhibition of 5-HT reuptake by the parent com- determine whether pharmacokinetic interactions could ex- pounds, and through their major circulating des-ethylated me- plain synergistic findings with particular drug combinations. tabolite, (dex)norfenfluramine, which is a 5-HT reuptake inhib- Methods Isobolographic analyses were performed in which itor, a 5-HT and noradrenaline releasing agent, and a potent phentermine was paired with either dexfenfluramine, the 5- agonist at postsynaptic 5-HT2 receptors (Curzon et al.
    [Show full text]
  • (19) United States (12) Patent Application Publication (10) Pub
    US 20130289061A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2013/0289061 A1 Bhide et al. (43) Pub. Date: Oct. 31, 2013 (54) METHODS AND COMPOSITIONS TO Publication Classi?cation PREVENT ADDICTION (51) Int. Cl. (71) Applicant: The General Hospital Corporation, A61K 31/485 (2006-01) Boston’ MA (Us) A61K 31/4458 (2006.01) (52) U.S. Cl. (72) Inventors: Pradeep G. Bhide; Peabody, MA (US); CPC """"" " A61K31/485 (201301); ‘4161223011? Jmm‘“ Zhu’ Ansm’ MA. (Us); USPC ......... .. 514/282; 514/317; 514/654; 514/618; Thomas J. Spencer; Carhsle; MA (US); 514/279 Joseph Biederman; Brookline; MA (Us) (57) ABSTRACT Disclosed herein is a method of reducing or preventing the development of aversion to a CNS stimulant in a subject (21) App1_ NO_; 13/924,815 comprising; administering a therapeutic amount of the neu rological stimulant and administering an antagonist of the kappa opioid receptor; to thereby reduce or prevent the devel - . opment of aversion to the CNS stimulant in the subject. Also (22) Flled' Jun‘ 24’ 2013 disclosed is a method of reducing or preventing the develop ment of addiction to a CNS stimulant in a subj ect; comprising; _ _ administering the CNS stimulant and administering a mu Related U‘s‘ Apphcatlon Data opioid receptor antagonist to thereby reduce or prevent the (63) Continuation of application NO 13/389,959, ?led on development of addiction to the CNS stimulant in the subject. Apt 27’ 2012’ ?led as application NO_ PCT/US2010/ Also disclosed are pharmaceutical compositions comprising 045486 on Aug' 13 2010' a central nervous system stimulant and an opioid receptor ’ antagonist.
    [Show full text]
  • Reflections on Contagious Off-Label Use of Phentermine and Fenfluramine
    University of Massachusetts Medical School eScholarship@UMMS Population and Quantitative Health Sciences Publications Population and Quantitative Health Sciences 2008 Weighing in 10 Years Later: Reflections on Contagious Off-Label Use of Phentermine and Fenfluramine Regina C. Grebla Brown University Et al. Let us know how access to this document benefits ou.y Follow this and additional works at: https://escholarship.umassmed.edu/qhs_pp Part of the Bioinformatics Commons, Biostatistics Commons, Epidemiology Commons, and the Health Services Research Commons Repository Citation Grebla RC, Waring ME. (2008). Weighing in 10 Years Later: Reflections on Contagious Off-Label Use of Phentermine and Fenfluramine. Population and Quantitative Health Sciences Publications. Retrieved from https://escholarship.umassmed.edu/qhs_pp/379 This material is brought to you by eScholarship@UMMS. It has been accepted for inclusion in Population and Quantitative Health Sciences Publications by an authorized administrator of eScholarship@UMMS. For more information, please contact [email protected]. Looking Back, Learning Forward History doesn’t repeat itself -- at best it sometimes rhymes. Mark Twain Weighing in 10 years later: Reflections on Contagious off-label use of Phentermine and Fenfluramine Contributed by Regina C. Grebla, MGA, MPH PhD(c) Molly E. Waring AM PhD(c) Graduate students, Brown Medical School The piece for this edition of Scribe focuses on the phentermine and fenfluramine story. This edition comes to you from two students in my advanced pharmacoepidemiology course, shortened significantly to meet the needs of this column. I welcome contributions which stay true to the theme of reflecting and learning about past challenges in pharmacoepidemiology. Please forward ideas to : [email protected] .
    [Show full text]
  • Selective Labeling of Serotonin Receptors Byd-[3H]Lysergic Acid
    Proc. Nati. Acad. Sci. USA Vol. 75, No. 12, pp. 5783-5787, December 1978 Biochemistry Selective labeling of serotonin receptors by d-[3H]lysergic acid diethylamide in calf caudate (ergots/hallucinogens/tryptamines/norepinephrine/dopamine) PATRICIA M. WHITAKER AND PHILIP SEEMAN* Department of Pharmacology, University of Toronto, Toronto, Canada M5S 1A8 Communicated by Philip Siekevltz, August 18,1978 ABSTRACT Since it was known that d-lysergic acid di- The objective in this present study was to improve the se- ethylamide (LSD) affected catecholaminergic as well as sero- lectivity of [3H]LSD for serotonin receptors, concomitantly toninergic neurons, the objective in this study was to enhance using other drugs to block a-adrenergic and dopamine receptors the selectivity of [3HJISD binding to serotonin receptors in vitro by using crude homogenates of calf caudate. In the presence of (cf. refs. 36-38). We then compared the potencies of various a combination of 50 nM each of phentolamine (adde to pre- drugs on this selective [3H]LSD binding and compared these clude the binding of [3HJLSD to a-adrenoceptors), apmo ie, data to those for the high-affinity binding of [3H]serotonin and spiperone (added to preclude the binding of [3H[LSD to (39). dopamine receptors), it was found by Scatchard analysis that the total number of 3H sites went down to 300 fmol/mg, compared to 1100 fmol/mg in the absence of the catechol- METHODS amine-blocking drugs. The IC50 values (concentrations to inhibit Preparation of Membranes. Calf brains were obtained fresh binding by 50%) for various drugs were tested on the binding of [3HLSD in the presence of 50 nM each of apomorphine (A), from the Canada Packers Hunisett plant (Toronto).
    [Show full text]
  • Pharmacology and Toxicology of Amphetamine and Related Designer Drugs
    Pharmacology and Toxicology of Amphetamine and Related Designer Drugs U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES • Public Health Service • Alcohol Drug Abuse and Mental Health Administration Pharmacology and Toxicology of Amphetamine and Related Designer Drugs Editors: Khursheed Asghar, Ph.D. Division of Preclinical Research National Institute on Drug Abuse Errol De Souza, Ph.D. Addiction Research Center National Institute on Drug Abuse NIDA Research Monograph 94 1989 U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES Public Health Service Alcohol, Drug Abuse, and Mental Health Administration National Institute on Drug Abuse 5600 Fishers Lane Rockville, MD 20857 For sale by the Superintendent of Documents, U.S. Government Printing Office Washington, DC 20402 Pharmacology and Toxicology of Amphetamine and Related Designer Drugs ACKNOWLEDGMENT This monograph is based upon papers and discussion from a technical review on pharmacology and toxicology of amphetamine and related designer drugs that took place on August 2 through 4, 1988, in Bethesda, MD. The review meeting was sponsored by the Biomedical Branch, Division of Preclinical Research, and the Addiction Research Center, National Institute on Drug Abuse. COPYRIGHT STATUS The National Institute on Drug Abuse has obtained permission from the copyright holders to reproduce certain previously published material as noted in the text. Further reproduction of this copyrighted material is permitted only as part of a reprinting of the entire publication or chapter. For any other use, the copyright holder’s permission is required. All other matieral in this volume except quoted passages from copyrighted sources is in the public domain and may be used or reproduced without permission from the Institute or the authors.
    [Show full text]
  • Amphetamine Derivatives Interact with Both Plasma Membrane and Secretory Vesicle Biogenic Amine Transporters
    '4 0026-895X/93/061227-05503.00/0 Copyright © by The American Society for Pharmacology and Experimental Therapeutics AIl rights of reproduction in any form reserved. MOLECULAR PHARMACOLOGY, 44:1227-1231 Amphetamine Derivatives Interact with Both Plasma Membrane and Secretory Vesicle Biogenic Amine Transporters SHIMON SCHULDINER, SONIA STEINER-MORDOCH, RODRIGO YELIN, STEPHEN C. WALL, and GARY RUDNICK Departmentof Pharmacology,YaleUniversitySchool of Medicine,New Haven,CT 06510 (S.C.W.,G.R.) andAlexanderSilbermanInstituteof Life Sciences,TheHebrew University,GivatRam, Jerusalem,Israel (S.S.,S.S.-M., R.Y.) ReceivedJune 7, 1993; Accepted September 16, 1993 SUMMARY The interaction of fenfluramine, 3,4-methylenedioxymethamphe- porter, fenfiuramine inhibited serotonin transport and dissipated tamine (MDMA), and p-chloroamphetamine (PCA) with the plate- the transmembrane pH difference (ApH) that drives amine up- let plasma membrane serotonin transporter and the vesicular take. The use of [3H]reserpine-binding measurements to deter- amine transporter were studied using both transport and binding mine drug interaction with the vesicular amine transporter al- measurements. Fenfluramine is apparently a substrate for the lowed assessment of the relative ability of MDMA, PCA, and plasma membrane transporter, and consequently inhibits both fenfluramine to bind to the substrate site of the vesicular trans- serotonin transport and imipramine binding. Moreover, fenflura- porter. These measurements permit a distinction between inhi- mine exchanges with internal [3H]serotonin in a plasma mem- bition of vesicular serotonin transport by directly blocking vesic- brane transporter-mediated reaction that requires NaCI and is ular amine transport and by dissipating ApH. The results indicate blocked by imipramine. These properties are similar to those of that MDMA and fenfluramine inhibit by both mechanisms but MDMA and PCA as previously described.
    [Show full text]
  • Presented to the Graduate Council of the University of North Texas in Partial Fulfillment of the Requirements for the Degree Of
    3-7? CHEMICAL IONIZATION (CI) GC/MS ANALYSIS OF UNDERIVATIZED AMPHETAMINES FOLLOWED BY CHIRAL DERIVATIZATION TO IDENTIFY d AND 1-ISOMERS WITH ION TRAP MASS SPECTROMETRY THESIS Presented to the Graduate Council of the University of North Texas in Partial Fulfillment of the Requirements for the Degree of MASTER OF SCIENCE (Pharmacology) By John A. Tarver B.S.,B.A. May, 1991 Tarver, John A. Chemical Ionization (CI) GC/MS Analysis of Underivatized Amphetamines Followed by Chiral Derivatiza- tion to Identify d and 1-Isomers with Ion Trap Mass Spectro- metry. Master of Science (Biomedical Sciences), May, 1991, 26 pp., 9 figures, bibliography, 20 titles. An efficient two step procedure has been developed using CI GC/MS for analyzing amphetamines and related compounds. The first step allows the analysis of underiv- atized amphetamines with the necessary sensitivity and specificity to give spectral identification, including differentiation between methamphetamine and phentermine. The second step involves preparing a chiral derivative of the extract to identify d and 1-isomeric composition. TABLE OF CONTENTS Page LIST OF ILLUSTRATIONS.......... ... .. .. .......... iv INTRODUCTION .1........................... EXPERIMENTAL MATERIALS ...--- - - - - ----... -....-..... 15 METHODS --------------------.---...... 15 RESULTS AND DISCUSSION ...-..-..................... 17 CONCLUSION - - - - - -- - - - - --- - --- . - . 23 APPENDIX......... ---. -----....-.-. ----.. -........ 24 REFERENCES ----------------------------.. --. ...---.. 28 iii LIST OF ILLUSTRATIONS
    [Show full text]
  • Health and Human Services Committee
    HEALTH AND HUMAN SERVICES COMMITTEE MEETING AGENDA Date & Time of Meeting: Monday, August 26, 2019 at 4:00 p.m. Meeting Location: Courthouse Assembly Room (B105), 500 Forest Street, Wausau WI Health & Human Services Committee Members: Matt Bootz, Chair; Tim Buttke, Vice-chair, Bill Miller; Donna Krause, Mary Ann Crosby, Maynard Tremelling, Katie Rosenberg Marathon County Mission Statement: Marathon County Government serves people by leading, coordinating, and providing county, regional, and statewide initiatives. It directly or in cooperation with other public and private partners provides services and creates opportunities that make Marathon County and the surrounding area a preferred place to live, work, visit, and do business. (Last updated: 12-20-05) Health & Human Services Committee Mission Statement: Provide leadership for the implementation of the strategic plan, monitoring outcomes, reviewing and recommending to the County Board policies related to health and human services initiatives of Marathon County. 1. Call Meeting to Order 2. Public Comment (15 minute limit) 3. Approval of the July 22, 2019, Committee meeting minutes. 4. Policy Issues for Discussion and Possible Action: A. Referral from the Board of Health – Creation of a Workplace Naloxone Use Program 1) Policy Question – should the committee direct the County Administrator to develop a workplace Naloxone Use Program? 5. Operational Functions required by Statute, Ordinance, or Resolution: None 6. Educational Presentations/Outcome Monitoring Reports and Committee Discussion A. Marathon County 2018-2022 Strategic Plan – discussion with Board Vice-Chair 1) Review of Objectives where the committee has been designated at “lead committee” 2) What discussions has the committee had to move the objectives forward and what discussions should it have in the future? B.
    [Show full text]
  • Recommended Methods for the Identification and Analysis Of
    Vienna International Centre, P.O. Box 500, 1400 Vienna, Austria Tel: (+43-1) 26060-0, Fax: (+43-1) 26060-5866, www.unodc.org RECOMMENDED METHODS FOR THE IDENTIFICATION AND ANALYSIS OF AMPHETAMINE, METHAMPHETAMINE AND THEIR RING-SUBSTITUTED ANALOGUES IN SEIZED MATERIALS (revised and updated) MANUAL FOR USE BY NATIONAL DRUG TESTING LABORATORIES Laboratory and Scientific Section United Nations Office on Drugs and Crime Vienna RECOMMENDED METHODS FOR THE IDENTIFICATION AND ANALYSIS OF AMPHETAMINE, METHAMPHETAMINE AND THEIR RING-SUBSTITUTED ANALOGUES IN SEIZED MATERIALS (revised and updated) MANUAL FOR USE BY NATIONAL DRUG TESTING LABORATORIES UNITED NATIONS New York, 2006 Note Mention of company names and commercial products does not imply the endorse- ment of the United Nations. This publication has not been formally edited. ST/NAR/34 UNITED NATIONS PUBLICATION Sales No. E.06.XI.1 ISBN 92-1-148208-9 Acknowledgements UNODC’s Laboratory and Scientific Section wishes to express its thanks to the experts who participated in the Consultative Meeting on “The Review of Methods for the Identification and Analysis of Amphetamine-type Stimulants (ATS) and Their Ring-substituted Analogues in Seized Material” for their contribution to the contents of this manual. Ms. Rosa Alis Rodríguez, Laboratorio de Drogas y Sanidad de Baleares, Palma de Mallorca, Spain Dr. Hans Bergkvist, SKL—National Laboratory of Forensic Science, Linköping, Sweden Ms. Warank Boonchuay, Division of Narcotics Analysis, Department of Medical Sciences, Ministry of Public Health, Nonthaburi, Thailand Dr. Rainer Dahlenburg, Bundeskriminalamt/KT34, Wiesbaden, Germany Mr. Adrian V. Kemmenoe, The Forensic Science Service, Birmingham Laboratory, Birmingham, United Kingdom Dr. Tohru Kishi, National Research Institute of Police Science, Chiba, Japan Dr.
    [Show full text]
  • Psychedelics in Psychiatry: Neuroplastic, Immunomodulatory, and Neurotransmitter Mechanismss
    Supplemental Material can be found at: /content/suppl/2020/12/18/73.1.202.DC1.html 1521-0081/73/1/202–277$35.00 https://doi.org/10.1124/pharmrev.120.000056 PHARMACOLOGICAL REVIEWS Pharmacol Rev 73:202–277, January 2021 Copyright © 2020 by The Author(s) This is an open access article distributed under the CC BY-NC Attribution 4.0 International license. ASSOCIATE EDITOR: MICHAEL NADER Psychedelics in Psychiatry: Neuroplastic, Immunomodulatory, and Neurotransmitter Mechanismss Antonio Inserra, Danilo De Gregorio, and Gabriella Gobbi Neurobiological Psychiatry Unit, Department of Psychiatry, McGill University, Montreal, Quebec, Canada Abstract ...................................................................................205 Significance Statement. ..................................................................205 I. Introduction . ..............................................................................205 A. Review Outline ........................................................................205 B. Psychiatric Disorders and the Need for Novel Pharmacotherapies .......................206 C. Psychedelic Compounds as Novel Therapeutics in Psychiatry: Overview and Comparison with Current Available Treatments . .....................................206 D. Classical or Serotonergic Psychedelics versus Nonclassical Psychedelics: Definition ......208 Downloaded from E. Dissociative Anesthetics................................................................209 F. Empathogens-Entactogens . ............................................................209
    [Show full text]
  • Summary of Risk Management Plan for Fintepla (Fenfluramine) This Is a Summary of the Risk Management Plan (RMP) for Fintepla
    Summary of risk management plan for Fintepla (fenfluramine) This is a summary of the risk management plan (RMP) for Fintepla. The RMP details important risks of Fintepla, how these risks can be minimised, and how more information will be obtained about Fintepla's risks and uncertainties (missing information). Fintepla's summary of product characteristics (SmPC) and its package leaflet give essential information to healthcare professionals and patients on how Fintepla should be used. This summary of the RMP for Fintepla should be read in the context of all this information including the assessment report of the evaluation and its plain-language summary, all which is part of the European Public Assessment Report (EPAR). Important new concerns or changes to the current ones will be included in updates of Fintepla's RMP. I. The medicine and what it is used for Fintepla is authorised for the treatment of seizures associated with Dravet syndrome as an add-on therapy to other antiepileptic medicines for patients 2 years of age and older (see SmPC for the full indication). It contains fenfluramine as the active substance and it is given by mouth. Further information about the evaluation of Fintepla’s benefits can be found in Fintepla’s EPAR, including in its plain-language summary, available on the EMA website, under the medicine’s webpage https://www.ema.europa.eu/en/medicines/human/EPAR/fintepla. II. Risks associated with the medicine and activities to minimise or further characterise the risks Important risks of Fintepla, together with measures to minimise such risks and the proposed studies for learning more about Fintepla's risks, are outlined below.
    [Show full text]
  • Frequently Asked Questions
    Frequently Asked Questions What are the requirements for license renewal? Licenses Expire Contact Hours Required Biennially on or before November 1 of the even or odd years. 30 How do I complete this course and receive my certificate of completion? Go to Pharmacy.EliteCME.com and follow the prompts. You will be able to print your certificate immediately upon completion of the course. How much will it cost? Cost of Courses Course Title Contact Hours Price Overview of Arizona Pharmacy Law - Mandatory 3 $12.00 Best Practices for Prescribing Opioids in Chronic Non-Cancer Pain 3 $12.00 Complications of Chronic Kidney Disease 2 $8.00 Diabetic Medications and Insulin Pump Therapies 6 $24.00 Drug Administration 2 $8.00 Law and Ethics: What the Pharmacy Professional Should Know 3 $12.00 Methicillin-Resistant Staphylococcus Aureus: Prevention and Treatment 2 $8.00 Pain Management Awareness for Pharmacists 2 $8.00 Patient Safety and Medication Errors 3 $12.00 Pharmacist Responsibilities in the Management of Controlled Substances 1 $4.00 Shingles Disease Process and Vaccination for Pharmacists & Pharmacy Technicians 2 $8.00 Sterile Drug Preparation 1 $4.00 BEST VALUE SAVE $21.00 Entire 30-hour Course 30 $99.00 Are you an Arizona board-approved provider? State board’s rules/statutes state that any course approved by the Accreditation Council for Pharmaceutical Education (ACPE) is accepted. All of our courses are accredited by ACPE. Are my credit hours reported to the Arizona board? No. The board performs random audits at which time proof of continuing education must be provided. Your hours will be electronically reported to CPE Monitor within 10 business days.
    [Show full text]